For those looking for great candidates, here are two in the healthcare sector: Merck ( MRK 2.48%) and Pfizer ( PFE 0.76%).

Zai Lab and Pfizer have entered a strategic collaboration for the commercialisation of XACDURO in mainland China.

The plant is a key producer of sterile injectables, responsible for manufacturing nearly 25% of all Pfizer sterile injectable ...

Pfizer's stock appears undervalued with a high dividend yield of 6.8%, making it a potential long-term investment despite low growth expectations. The company reported strong Q3 results with 31.2% YoY ...

Meanwhile, Pfizer's forward earnings multiple is only 8.3. This stark contrast stems from the companies' growth prospects.

Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for ...

Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14% on an operational basis due to ...

Zai Lab and Pfizer have partnered for the commercialization of Xacduro (sulbactam-durlobactam) in China, targeting carbapenem ...

We recently compiled a list of the Jim Cramer Talked About These 11 Stocks Recently. In this article, we are going to take a ...

“We are committed to holding these companies accountable for the safety of their products,” Dimopoulos said in the statement.

The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. The ...

Recently, Pfizer has launched a specialised centre at a hospital in Gurugram and is planning to start more such centres to ...